Making vaccines “on demand”
Open Access
- 19 September 2013
- journal article
- review article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 9 (9) , 1877-1884
Abstract
The integrated US Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) has made great strides in strategic preparedness and response capabilities. There have been numerous advances in planning, biothreat countermeasure development, licensure, manufacturing, stockpiling and deployment. Increased biodefense surveillance capability has dramatically improved, while new tools and increased awareness have fostered rapid identification of new potential public health pathogens. Unfortunately, structural delays in vaccine design, development, manufacture, clinical testing and licensure processes remain significant obstacles to an effective national biodefense rapid response capability. This is particularly true for the very real threat of “novel pathogens” such as the avian-origin influenzas H7N9 and H5N1, and new coronaviruses such as hCoV-EMC. Conventional approaches to vaccine development, production, clinical testing and licensure are incompatible with the prompt deployment needed for an effecti...Keywords
This publication has 54 references indexed in Scilit:
- Identification of Class I HLA T Cell Control Epitopes for West Nile VirusPLOS ONE, 2013
- Examination of Influenza Specific T Cell Responses after Influenza Virus Challenge in Individuals Vaccinated with MVA-NP+M1 VaccinePLOS ONE, 2013
- Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in HumansClinical Infectious Diseases, 2012
- Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4+ T cells against the swine-origin H1N1 influenza virusVaccine, 2011
- HelicoVax: Epitope-based therapeutic Helicobacter pylori vaccination in a mouse modelVaccine, 2011
- Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3′ to 5′ exonuclease activity essential for immune suppressionProceedings of the National Academy of Sciences, 2011
- VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response aloneVaccine, 2011
- Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human populationProceedings of the National Academy of Sciences, 2009
- Microneedle-Based Vaccines2009
- A consensus epitope prediction approach identifies the breadth of murine TCD8+-cell responses to vaccinia virusNature Biotechnology, 2006